Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology company developing bispecific and trispecific immunotherapies for cancer, and its news flow reflects both scientific progress and capital markets activity. On this APVO news page, readers can follow company-issued updates and third-party coverage related to its immune-oncology pipeline and corporate developments.
Aptevo’s recent press releases highlight key milestones for mipletamig, its CD123 x CD3 T-cell engager in the RAINIER Phase 1b/2 trial for frontline acute myeloid leukemia. News items include reports of remission rates in early cohorts, safety observations such as the absence of cytokine release syndrome in frontline patients treated to date in reported cohorts, and presentations of data at major medical meetings like the American Society of Hematology (ASH).
Investors and clinicians can also track announcements on Aptevo’s expanding CD3-engaging portfolio, including bispecific candidates APVO442 (PSMA x CD3) for prostate cancer and APVO455 (Nectin-4 x CD3) for multiple solid tumor types, as well as trispecific candidates APVO451 and APVO452 that combine tumor targeting, T-cell activation, and CD40-mediated costimulation. News coverage often details preclinical data presented at scientific conferences such as the Society for Immunotherapy of Cancer (SITC).
In addition to R&D and clinical trial updates, APVO news includes quarterly financial results, descriptions of its cash runway, and disclosures about equity financings, including at-the-market offerings, registered direct offerings, and an equity line of credit structure. Regulatory and governance developments, such as reverse stock split implementation, Nasdaq compliance updates, and amendments to rights agreements, are also reported.
By reviewing the APVO news feed, readers can monitor how Aptevo communicates progress on its ADAPTIR and ADAPTIR-FLEX platform-derived candidates, its interactions with the capital markets, and its participation in scientific and industry conferences.
Aptevo (Nasdaq: APVO) announced executive leadership transitions effective April 1, 2026: Marvin White will move from President & CEO to Executive Chair and Jeff Lamothe will become President & CEO and join the Board; John E. Niederhuber, M.D., will become Lead Independent Director.
The company highlighted clinical progress (more than 100 patients treated with mipletamig), an expanded eight-molecule pipeline including trispecific programs, a partnership with Alligator Bioscience, and a financial runway into 2029 including a $60 million equity line.
Aptevo Therapeutics (NASDAQ: APVO) entered a $60 million equity line of credit with Yorkville Advisors to provide incremental, market-based capital access. Combined with cash on hand, the fully leveraged facility is stated to extend Aptevo's funding runway into 2029 to support clinical and preclinical multispecific oncology programs. Proceeds will fund ongoing clinical development, advance preclinical programs, and general corporate purposes. The company retains discretion to draw on the facility; terms note minimal fees and no warrants. Aptevo's pipeline includes five CD3-engaging assets led by mipletamig (CD123×CD3), evaluated in >100 patients with reported high remission rates and no observed cytokine release syndrome in frontline patients to date.
Aptevo Therapeutics (NASDAQ:APVO) will implement a 1-for-18 reverse stock split, effective December 29, 2025 at 5:01 p.m. ET, with split-adjusted trading expected to begin on Nasdaq at market open on December 30, 2025.
Every 18 pre-split shares will convert into one post-split share, reducing outstanding common stock from approximately 18 million to approximately 1 million (subject to rounding and issuances). The company will not change its trading symbol APVO. Outstanding options, RSUs, warrants and equity-plan share counts will be adjusted; fractional shares will be cashed out. The split was approved by stockholders July 24, 2025 and the board set the final ratio on December 17, 2025.
Aptevo Therapeutics (NASDAQ:APVO) presented preliminary Phase 1b/2 RAINIER data for mipletamig (CD123 x CD3) combined with azacitidine and venetoclax for newly diagnosed AML patients unfit for intensive chemotherapy at ASH on December 8, 2025.
Key readouts: 100% of patients in Cohorts 1–3 remained free of cytokine release syndrome (CRS); 93% ORR among evaluable patients; 87% CR/CRi; 73% CR; 60% of MRD-evaluable CR/CRi patients were MRD negative; 43% of ORR patients had TP53 mutations. Median age was 75. The triplet was generally well tolerated; infusion-related reactions and hematologic events were the most common adverse events. The trial is continuing enrollment across additional dose levels.
Aptevo (NASDAQ:APVO) presented first preclinical data for its trispecific antibody candidate APVO451 at the Society for Immunotherapy of Cancer Annual Meeting on November 8, 2025. APVO451 targets nectin-4 to localize activity, uses a CRIS-7-derived CD3 binding domain to activate T cells without observed cytokine release syndrome in related programs, and engages CD40 to restore antigen-presenting cell function.
Key preclinical findings showed tumor-localized T‑cell and APC activation, superior elimination of nectin-4+ tumor cells versus a standard CD3 engager in suppressive tumor models, and ongoing IND‑enabling preclinical studies.
Aptevo Therapeutics (Nasdaq:APVO) reported 3Q25 results and a business update on November 6, 2025. Key clinical highlights include 89% remission among evaluable frontline AML patients across two trials treated with mipletamig combinations and no cytokine release syndrome (CRS) observed in those frontline patients to date. The Company introduced two trispecific T-cell engagers, APVO451 and APVO452, expanding its CD3 portfolio to five molecules. Financially, Aptevo raised $18.7M in Q3 and $4.1M post-quarter, holding $21.1M cash at 9/30/25 (pro forma $25.2M) and stating runway into 4Q26.
Aptevo (Nasdaq:APVO) announced participation in multiple financial, industry and scientific conferences in Q4 2025 to highlight clinical and R&D progress.
Key events:
- ROTH Healthcare Opportunities – Oct 9, 2025 (NYC): panel on novel AML therapies and mipletamig trial outcomes.
- BIO-Europe – Nov 3-5, 2025 (Vienna) with digital partnering Nov 11-12.
- SITC 2025 – Nov 5-9: R&D poster on a trispecific targeting Nectin-4, CD3 and CD40.
- ASH 2025 – Dec 6-9: interim Phase 1b/2 RAINIER results for mipletamig in frontline AML.
Investor meetings available by contacting investor relations.
Aptevo Therapeutics (NASDAQ:APVO) announced breakthrough results from Cohort 3 of its Phase 1b/2 RAINIER trial evaluating mipletamig, a CD123 x CD3 bispecific antibody, in combination with venetoclax and azacitidine for newly diagnosed AML patients unfit for intensive chemotherapy.
Key highlights include a 100% remission rate (CR/CRi) at the highest dose level, with 40% of patients achieving MRD-negative status. Notably, the trial reported no dose-limiting toxicities or cytokine release syndrome, demonstrating a favorable safety profile. The trial is progressing with Cohort 4 now open for enrollment, and results are expected to be presented at a major medical conference in Q4.
Aptevo Therapeutics (NASDAQ:APVO) has expanded its oncology pipeline with two new trispecific candidates, APVO452 and APVO451, targeting prostate cancer and multiple solid tumors. These therapeutics leverage the company's proprietary ADAPTIR-FLEX platform and build upon clinical validation from mipletamig, their lead CD3-directed candidate.
APVO452 targets PSMA, CD3, and CD40 for prostate cancers, while APVO451 targets Nectin-4, CD3, and CD40 for various solid tumors. Both therapeutics are designed to simultaneously engage tumor antigens, activate T cells, and modulate immunosuppressive cells in the tumor microenvironment.
This expansion brings Aptevo's pipeline to eight bispecific and trispecific candidates, including five molecules utilizing their CRIS-7-derived CD3 pathway, positioning them as a leader in next-generation T cell engagers for both hematologic and solid tumor cancers.
Aptevo Therapeutics (Nasdaq:APVO) highlighted APVO442, its preclinical CD3-engaging bispecific antibody for prostate cancer treatment. Built on the company's ADAPTIR-FLEX platform, APVO442 uses the same CRIS-7-derived anti-CD3 binding domain as mipletamig but is specifically engineered for solid tumors.
The candidate is designed to selectively activate T cells within PSMA-expressing tumor microenvironment, potentially offering improved safety and maintained anti-tumor potency. Preclinical data demonstrates effective localization to prostate tumors while potentially sparing healthy tissue.
The targeted market is significant, with prostate cancer being the second most common cancer in men, representing over 300,000 new U.S. cases annually. The global treatment market, currently at $14 billion, is projected to reach $24 billion within the next decade.
FAQ
What is the current stock price of Aptevo Therapeutics (APVO)?
What is the market cap of Aptevo Therapeutics (APVO)?
